Akero Therapeutics is Drug Discovery in United States that focus on Akero Therapeutics Inc business. Founded in 2017. They cover business area such as Akero Therapeutics Inc, transformative treatment, serious metabolic disease, high unmet medical need, its focus, nonalcoholic steatohepatitis, NASH, any approve therapy, property, nash pathogenesis.
2017
( 7 years old in 2024 )
Akero Therapeutics Inc
-
170 Harbor Way
3rd Floor
South San Francisco, CA 94080
United States
Private
Akero Therapeutics Inctransformative treatmentserious metabolic diseasehigh unmet medical needits focusnonalcoholic steatohepatitisNASHany approve therapypropertynash pathogenesis
* We use standard office opening hours in near Akero Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Akero Therapeutics is Drug Discovery business from United States that founded in 2017 (7 years old in 2024), Akero Therapeutics business is focusing on Akero Therapeutics Inc.
Akero Therapeutics headquarter office and corporate office address is located in 170 Harbor Way 3rd Floor South San Francisco, CA 94080 United States.
Akero Therapeutics was founded in United States.
In 2024, Akero Therapeutics is currently focus on Akero Therapeutics Inc sector.
Above is snippet of Google Trends for "Akero Therapeutics Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Akero Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
